Financial Performance - The company's revenue decreased by 18.5% from RMB 16,284 million in 2024H1 to RMB 13,273 million in 2025H1[35] - Gross profit decreased by 25.3% from RMB 11,655 million in 2024H1 to RMB 8,710 million in 2025H1[35] - Gross profit margin decreased by 6.0 percentage points from 71.6% in 2024H1 to 65.6% in 2025H1[35] - Reported profit attributable to shareholders of the Company decreased by 15.6% from RMB 3,020 million in 2024H1 to RMB 2,548 million in 2025H1[35] - Underlying profit attributable to shareholders of the Company decreased by 27.9% from RMB 3,217 million in 2024H1 to RMB 2,320 million in 2025H1[35] - Revenue from finished drugs decreased by 24.4% from RMB 13,549 million in 2024H1 to RMB 10,248 million in 2025H1[36] - Revenue from bulk vitamin C increased by 21.6% from RMB 984 million in 2024H1 to RMB 1,196 million in 2025H1[36] - Revenue from nervous system therapeutics decreased by 28.3% from RMB 5,236 million in 2024H1 to RMB 3,755 million in 2025H1[37] - Revenue from oncology therapeutics decreased significantly by 60.8% from RMB 2,683 million in 2024H1 to RMB 1,051 million in 2025H1[37] R&D and Pipeline - The company has 5 R&D centers located in China & the U S [6,99] - The company has approximately 200 innovative drugs and new formulations [6,99] - R&D expenses increased by 5.5% from RMB 2,542 million in 2024H1 to RMB 2,683 million in 2025H1[35] Business Development - The company has license-out agreements including a potential milestone payment of $105 billion for GLP-1, $522 billion for ROR1 ADC, $1955 billion for Irinotecan Liposome Injection, and $1225 billion for strategic collaboration [116]

Financial Performance - Total revenues decreased by 3.6%, from RMB 4041.8 million in 2024 1H to RMB 3894.5 million in 2025 1H[28] - Aviation information technology services revenue increased by 2.1%, from RMB 2265.0 million in 2024 1H to RMB 2313.4 million in 2025 1H[33] - Settlement and clearing services revenue increased by 12.4%, from RMB 278.0 million in 2024 1H to RMB 312.5 million in 2025 1H[33] - System integration services revenue decreased significantly by 38.5%, from RMB 679.8 million in 2024 1H to RMB 418.4 million in 2025 1H[33] - Income from technical support and products increased by 30.4%, from RMB 295.3 million in 2024 1H to RMB 385.0 million in 2025 1H[33] - Other income decreased by 10.2%, from RMB 307.2 million in 2024 1H to RMB 275.7 million in 2025 1H[33] - Total operating expenses decreased by 4.2%, from RMB 2535.3 million in 2024 1H to RMB 2427.9 million in 2025 1H[41] Operational Data - Total volume processed by the systems increased by 5.31% compared to 2024 1H and increased by 9.91% compared to 2019 1H[12] - The processing volume of China Airlines' system handled by China Aviation Information Corporation is about 360 million people, a year-on-year increase of 5.5% and a year-on-year increase of 12.5% compared to the same period in 2019[17] Future Investments - The company's capital expenditure commitment amounted to approximately RMB 1518.7 million as of June 30, 2025[47] - The relevant budget for Beijing Shunyi Park Phase II is approximately RMB 938.0 million, and the total expenditures for Shunyi Phase II Project not exceeding RMB 1032.0 million[51]

Antengene Pipeline Overview - Antengene is developing a diverse pipeline of Antibody Drug Conjugates (ADCs), Immuno-Oncology (IO) therapies, and treatments for Autoimmune Diseases [16, 102] - The company's "2+1" T Cell Engager (TCE) platform, AnTenGager, is designed with steric hindrance-masking technology to enhance therapeutic effect and safety [20, 109] ATG-022 (Claudin 18.2 ADC) - ATG-022, a Claudin 18.2 ADC, has shown efficacy across various CLDN18.2 expression levels in gastric cancer [20, 32, 48] - In CLDN18.2 moderate to high expressing GC (IHC 2+ > 20%) patients treated with ATG-022 at 2.4 mg/kg, the ORR was 40% (12/30), and the DCR was 90% (27/30) [20] - In CLDN18.2 low and ultra-low expressing GC (IHC 2+ ≤ 20%) patients, an efficacious dose range of 1.8-2.4 mg/kg of ATG-022 resulted in an ORR of 33.3% (6/18) and a DCR of 50% (9/18) [20] - The median progression-free survival (mPFS) in Gastric or GEJ Cancer with Moderate to High CLDN18 2 Expression (IHC 2+, >20%) Treated at 2 4 mg/kg is 6 97 months, with a 6-month progression-free survival (PFS6m) rate of 51 1% [53] - The company is planning to investigate ATG-022 in combination with Pembrolizumab and CAPOX in Advanced / Metastatic Claudin 18 2 Positive Gastric Cancer (1L) [64] - ATG-022 is estimated to have over US$5 billion in peak sales potential [68, 70] ATG-037 (Oral CD73 Small Molecule Inhibitor) - ATG-037, an oral CD73 small molecule inhibitor, has demonstrated efficacy in CPI-resistant Melanoma with an ORR of 36.4% (4/11) and a DCR of 100% (11/11) [20] - In CPI-resistant Non-small Cell Lung Cancer, ATG-037 showed an ORR of 21.4% (3/14) and a DCR of 71.4% (10/14) [20] - The Immuno-oncology (IO) market is estimated to be $140+ billion in 2028 [78] AnTenGager TCE Platform - ATG-201, a CD19 x CD3 TCE, is IND-enabling for B Cell Driven Autoimmune Diseases, demonstrating deep B cell depletion with low CRS [16, 20, 119] - ATG-106 (CDH6 x CD3) is a First-in-Class CDH6 TCE for Ovarian Cancer and Kidney Cancer [17, 103, 132]

Financial Performance - Revenue decreased by 3.1% from HK$392 million to HK$380 million[9, 17] - Profit attributable to equity shareholders decreased by 23.5% from HK$102 million to HK$77 million[9, 17] - Basic & Diluted Earnings per share decreased by 23.9% from HK 10.95 cents to HK 8.33 cents[17] - Gross Profit decreased by 29.6% from HK$147 million to HK$104 million[17] - The board declared an interim dividend of HK 2.50 cents per share[10] Financial Metrics - EBITDA Margin decreased from 77% to 69%[23] - Debt-equity ratio decreased from 14% to 12%[25] Revenue Breakdown - Transponder service accounts for 85.2% of the turnover[19] - Broadcast & Telecom accounts for 0.5% of the turnover[19] - Others accounts for 14.3% of the turnover[19] - Southeast Asia accounts for 65.1% of the turnover[19] - Greater China accounts for 22.6% of the turnover[19, 20] - Others accounts for 12.3% of the turnover[19]

Jiumaojiu International Holdings Limited 九毛九国际控股有限公司 Stock Code 股份代号: 9922 2025年中期业绩发布会 2025 Interim Results Presentation August 2025 Disclaimer This Results Announcement Presentation is for the purpose of your reference only. It is not the intention to provide, and you may not rely on these materials as providing, a complete or comprehensive analysis of the Company's financial or trading position or prospects. The information and opinions contained in this document are provided as at the date hereof and ar ...

中国石油化工股份有限公司 S I N O P E C C O R P. Forward-looking Statement This presentation and the presentation materials distributed herein include forward-looking statements. All statements, other than statements of historical facts, that address activities, events or developments that Sinopec Corp. expects or anticipates will or may occur in the future (including but not limited to projections, targets, reserves and other estimates and business plans) are forward-looking statements. Sinopec Corp.'s actual results o ...

Financial Performance - Revenue increased by 3.3% year-over-year to RMB 14,817 million[14] - Net profit was RMB 1,737 million, with a net profit margin of 11.7%[14] - Net operating cash inflow decreased by 11.7% year-over-year to RMB 2,411 million[14] - Gross profit margin decreased by 0.4 percentage points year-over-year to 50.0%[14] - The Board declared an interim dividend of RMB 33.59 cents per ordinary share, with a payout ratio of 50%[14] Channel Performance - Overall channels retail sell-through increased by low-single-digit year-over-year[14] - Offline channel new product sell-through accounted for 84%[14, 21] - Wholesale revenue increased by 5% year-over-year[29] - Direct retail business revenue decreased by 4% year-over-year[34] - Online traffic increased by low-teens[111] Inventory and Working Capital - Channel inventory increased by low-single-digit year-over-year[14] - Company inventory cost amount increased by mid-single-digit year-over-year[103] - The percentage of gross average working capital to revenue was 7.3%[14]

Financial Performance Highlights - The Group's insurance revenue reached RMB 280250 million, a 71% increase[103, 104] - Net profit attributable to equity holders of the company increased by 140% to RMB 26671 million[18, 104] - The Group's consolidated net assets increased by 63% to RMB 3906 billion[20, 43] - Total investment yield (annualized) increased by 09 percentage points to 50%[25, 82, 104] - PICC P&C's combined ratio decreased by 14 percentage points to 948%[27, 59, 104] Segment Performance - PICC P&C's insurance revenue increased by 56% to RMB 249040 million[59, 103, 104] - PICC Life's insurance revenue increased significantly by 325% to RMB 14018 million[70, 103, 104] - PICC Health's insurance revenue increased by 132% to RMB 15603 million[76, 103, 104] Business Growth and Structure Optimization - Group premiums income increased by 64% to RMB 4546 billion[30] - Life & Health premiums income increased by 138%[33] - Total insurance investment assets increased by 72% to RMB 17607 billion[34] Key Initiatives and Focus Areas - The group will focus on strengthening core functions, promoting "Six Reforms", high-quality development, and risk prevention in the second half of 2025[92, 93, 94, 95]

Financial Performance - Sisram Medical's revenue decreased by 1.9% year-over-year to $165.5 million in H1 2025 [9, 71], but excluding North America, revenue grew 7.1% YoY [71] - Gross profit margin decreased by 2.4 percentage points to 60.0% [9, 71], due to product mix and decreased North America revenue [71] - Injectables revenue increased significantly by 218.1% year-over-year [9, 79], driven by geographical expansion and commercialization efforts [80] - Net profit decreased by 31.9% [70] Regional Performance - North America revenue decreased by 15.6% [10, 75] due to market headwinds [75] - APAC revenue increased by 17.6% [10, 75] due to the "Go-Direct" strategy [75] - Europe revenue declined slightly by 0.8% [75], but new EBD platforms saw notable growth [75] - Middle East and Africa revenue decreased by 9.7% [76] due to geopolitical tensions [76] Strategic Initiatives - The company is preparing for the launch of DAXXIFY in mainland China in H2 2025 [13, 45, 86] - The company is expanding global penetration of Alma Harmony, Alma IQ, and Universkin by Alma [86] - The company is driving injectables portfolio Revanesse and Profhilo growth in key markets [86] - The company is developing direct-sales offices in strategic regions [86]

Financial Performance - Core revenue (tissue and hygiene products) decreased by 3.1% to RMB 10.5 billion in 1H2025, compared to RMB 10.8 billion in 1H2024[9] - Profit attributable to shareholders decreased by 2.6% to RMB 1.37 billion in 1H2025, compared to RMB 1.41 billion in 1H2024[9] - Overall revenue slightly decreased by 0.2% to RMB 11,808.232 million in 1H2025, from RMB 11,835.893 million in 1H2024[15] - Basic earnings per share (EPS) decreased by 2.3% to RMB 1.206 in 1H2025, from RMB 1.234 in 1H2024[15] - Interim dividend per share remained unchanged at RMB 0.70[15] Business Segments - Tissue paper revenue increased by 3.2% to RMB 7,173.7 million in 1H2025, compared to RMB 6,950.578 million in 1H2024[18] - Hygiene products revenue decreased by 14.4% to RMB 3,303.839 million in 1H2025, compared to RMB 3,858.570 million in 1H2024[18] - Other revenue increased by 29.6% to RMB 1,330.693 million in 1H2025, compared to RMB 1,026.745 million in 1H2024[18] - Tissue paper sales in e-commerce and new retail channels rose significantly by 15.1%, accounting for nearly 40.9% of overall tissue sales[44] Financial Position - Net cash increased to RMB 6.4 billion in 1H2025, from RMB 5.4 billion in 1H2024[9] - Gearing ratio decreased to 77.5% in 1H2025, from 99.1% in 1H2024[9] - E-commerce and new retail channels sales Up 7.9%, to over RMB 4.06 billion[54] ESG - The company maintained a BBB rating from MSCI ESG Rating[11, 58]